Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Gating of RYR2 channels from the arrhythmic RYR2-P2328S mouse heart and some unexpected actions of flecainide

dc.contributor.authorDulhunty, Angela
dc.contributor.authorFraser, James A.
dc.contributor.authorHuang, Christopher
dc.contributor.authorSalvage, Samantha C.
dc.date.accessioned2024-05-02T04:58:46Z
dc.date.available2024-05-02T04:58:46Z
dc.date.issued2022
dc.date.updated2023-01-08T07:16:46Z
dc.description.abstractThe P2328S mutation in mice is associated with arrhythmia and spontaneous diastolic calcium release in atrial and ventricular myocytes and there is a corresponding leftward shift in the Ca2+-activation curve for mutant RYR2 channels from homozygous mouse hearts (Salvage et al. 2019. J Cell Sci. https://doi.org/10.1242/jcs.229039). P2328 is located in helical domain 1 (HD1) of RYR2. Local structural changes likely result when structurally active proline residues are replaced by structurally inert serine residues. We speculate that local structural changes in HD1 lead to sequential intradomain and interdomain stearic changes through the protein to the distant channel gate, which favor the open pore conformation. The drug flecainide prevents arrhythmia in humans and mouse models of CPVT by blocking NaV1.5 and RYR2 channels. Conventionally, flecainide blocks RYR2 channels in a voltage-dependent manner. We did not observe voltage-dependent pore block. This was possibly because, in contrast to previous studies, the only channel modulators that we used to produce end-diastolic control channel activity were 1 µM cytoplasmic Ca2+ and 1 mM luminal Ca2+. We observed previously unreported, voltage-independent increases in WT and P2328S channel activity at low flecainide concentrations, followed by a decline in activity at higher concentrations. The increase in activity dominated the effect of flecainide on P2328S channels. These effects suggested high-affinity flecainide binding to an activation site and lower-affinity binding to an inhibition site, both distant from the channel pore (Salvage et al. 2021. Cells. https://doi.org/10.3390/cells10082101). Unlike channel block by flecainide, the drug under our conditions stabilized intrinsic sub-conductance activity at +40 mV and -40 mV. Since flecainide effectively reduces CPVT arrythmia clinically and in animal models, we conclude that voltage-independent inhibition and voltage-dependent channel block prevail under cellular conditions. However, channel activation is important to note as it may be unmasked in other circumstances such as acquired cardiac disorders, mutations, or additional drug applications.en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn0022-1295en_AU
dc.identifier.urihttp://hdl.handle.net/1885/317237
dc.language.isoen_AUen_AU
dc.provenanceThis article is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).en_AU
dc.rights© 2021 Dulhunty et al.en_AU
dc.rights.licenseCreative Commons License (Attribution–Noncommercial–Share Alike 4.0 International licenseen_AU
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0/en_AU
dc.titleGating of RYR2 channels from the arrhythmic RYR2-P2328S mouse heart and some unexpected actions of flecainideen_AU
dc.typeConference paperen_AU
dcterms.accessRightsOpen Accessen_AU
local.contributor.affiliationDulhunty, Angela, College of Health and Medicine, ANUen_AU
local.contributor.affiliationFraser, James A., University of Cambridgeen_AU
local.contributor.affiliationHuang, Christopher, University of Cambridgeen_AU
local.contributor.affiliationSalvage, Samantha C., University of Cambridgeen_AU
local.contributor.authoruidDulhunty, Angela, u8404877en_AU
local.description.notesImported from ARIESen_AU
local.identifier.absfor320801 - Cell physiologyen_AU
local.identifier.absfor310110 - Receptors and membrane biologyen_AU
local.identifier.absfor320599 - Medical biochemistry and metabolomics not elsewhere classifieden_AU
local.identifier.ariespublicationa383154xPUB24602en_AU
local.identifier.doi10.1085/jgp.2021ecc42en_AU
local.identifier.essn1540-7748en_AU
local.identifier.scopusID2-s2.0-85121958164
local.publisher.urlhttps://rupress.org/en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Gating of RYR2 channels from the arrhythmic RYR2-P2328S.pdf
Size:
180.41 KB
Format:
Adobe Portable Document Format
Description: